New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
NCT ID NCT06648096
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Researchers will monitor safety and tumor response over 9 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Afatinib
- What this could lead to
- If successful, this could provide a targeted treatment option to control head and neck cancer in people with Fanconi anemia, who have limited options.
- What could go wrong
- This is an early-phase, small trial (25 people) with no control group. Afatinib may not shrink tumors or could cause significant side effects, especially in this vulnerable population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Catalonia, Spain
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?